Five years ago, Moderna, Inc. (MRNA) and Novavax, Inc. (NVAX) were two of the most talked about stocks across platforms like Seeking Alpha, social media, and likely in the national press of most ...

The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...

COVID-19 vaccination showed effectiveness in reducing hospitalizations and severe disease outcomes associated with the SARS-CoV-2 JN.1 lineage, according to a recent study published in JAMA Network ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

Gaithersburg-based Novavax said Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and ...

Modified agreement also includes the development of an updated vaccine in fall 2023 This contract will support the U.S. government's continued efforts to make Novavax' protein-based vaccine available ...

Novavax Inc. said this week that its COVID-19 vaccine would not receive regulatory clearance in the U.S. or the U.K. until at least July, while a shortage of materials has delayed its production ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax says its COVID-19 vaccine appears 89% effective, based on early findings from a British study. According to USA Today, the two-dose vaccine was just 60% effective in the South African trial.

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...